| Chronic Lymphocytic Leukemia |
1 |
1 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.87 |
| Medicare |
0 |
0.72 |
| B-Cell Lymphoma |
0 |
0.57 |
| Lymphoma |
0 |
0.54 |
| Neuroendocrine Tumor |
0 |
0.54 |
| Mantle Cell Lymphoma |
0 |
0.53 |
| Waldenstrom Macroglobulinemia |
0 |
0.47 |
| Leukemia |
0 |
0.18 |
| Anaphylaxis |
0 |
0.15 |
| Graft Versus Host Disease and Transplant Complications |
0 |
0.15 |
| Stem Cell Research and Therapy |
0 |
0.15 |
| Graft Versus Host Disease |
0 |
0.13 |
| Tyrosine Kinase Inhibitor |
0 |
0.13 |
| Biologic Therapy |
0 |
0.11 |
| Toxicology |
0 |
0.11 |
| Drug Costs |
0 |
0.09 |
| Graft |
0 |
0.09 |
| Grant |
0 |
0.09 |
| Hospital |
0 |
0.09 |
| Pharmacoeconomics |
0 |
0.09 |
| Pharmacoepidemiology |
0 |
0.09 |
| Remission |
0 |
0.09 |
| Tyrosine Kinase |
0 |
0.09 |